• Journal of Animal Science and Technology
• /
• v.54 no.3
• /
• pp.165-174
• /
• 2012

For horse breeders or managers, it is critical to understand the estrous cycle of mares. Breeding of mares cannot be successfully achieved throughout the whole year as mares breed seasonally. Mares are only able to breed when day length is more than 16 h, and this period is known as the breeding season. Their estrous cycle is approximately 21 days with 5-7 days of estrus and 14 to 15 days of a diestrus period. The estrous cycle of the mare is mainly controlled by gonadotropins, which control follicular development and ovulation. Mares exhibit unique ovulatory events which are not observed in other species. A LH surge occurs for several days, with levels of LH reaching their peak after ovulation. The LH level at the time of LH peak is lower than most other species. The unique anatomical structure of the ovaries of mares is known to limit the number of eggs ovulated. Several attempts have been made to develop chemical/hormonal agents which might be used to manipulate the timed ovulation of mares. Agents that have been tested include hCG, native GnRH, Deslorelin (Ovuplant, GnRH-agonist), Buserelin (GnRH analogue), equine pituitary extracts and equine chorionic gonadotropin (eCG or PMSG). However, the function, purity or stability of these agents is not reliable. Recombinant equine LH, an alternative agent for the timed ovulation, has been developed and tested for its biological activities, through the use of both in vitro and in vivo experiments. The reLH was suggested to be a reliable agent in inducing ovulation within 48 h after being administered through injection, when the size of dominant follicle is 35 mm in diameter.

• Development and Reproduction
• /
• v.4 no.2
• /
• pp.187-193
• /
• 2000

Gonad and blood samples were taken from the cultured female Korean sea bass, Lateolabrax japonicus from October to February between 1997 and 1999. Gonadosomatic index began to increase in November and reached the highest value in December (12.8$\pm$1.5) and January (14.8$\pm$3.5), and then decreased sharply in February (2.6$\pm$1.5, p<0.05). The ovarian oocytes developed to tertiary yolk stage and reached fully-Brown stage in December and January, and then underwent atresia without maturation and ovulation in February. The plasma estradio3-17 $\beta$ level increased from November, and reached the highest value in December (1,152.3$\pm$107.2 pg/ml) and January (1,315.4$\pm$99.5 pg/ml), after then decreased in February (P<0.05). The concentration of plasma 17 $\alpha$ ,20 $\beta$-dihydroxy-4-pregnen-3-one was not significantly changed at low levels (86.6$\pm$6.5∼93.8$\pm$2.8 pg/ml) during the experimental period (P<0.05). All the fish with fully-grown oocytes in the ovary were matured and ovulated by HCG injection. The number of floating eggs were 325,000$\pm$26,000 at HCG 1,000 luhg and 195,000$\pm$35,000 at 2,000 lUikg. There was no difference in fertilization rate and hatching rate of the eggs (P<0.05). Considering these results, we could infer that the ovarian oocyte of the cultured Korean sea bass were not matured and ovulated because of the lack of gonadotropin surge. Moreover, HCG injection could induce oocyte maturation and ovulation in the cultured fish, and the effective dose was 1,000 IU/kg.

• Clinical and Experimental Reproductive Medicine
• /
• v.31 no.4
• /
• pp.225-234
• /
• 2004

Objectives: To evaluate the efficacy of GnRH antagonist cetrorelix in women undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI) and to determine changes in serum hormone concentrations during cetrorelix administration. Methods: We performed a clinical trial on 30 patients undergoing COH with highly purified follicular stimulating hormone (HP-FSH) and gonadotropin releasing hormone antagonist (GnRHant), cetrorelix. FSH was administrated from day 2 or 3 of cycle with fixed dose and adjusted according to individual response. 0.25 mg of cetrorelix was injected daily subcutaneously from stimulation day 5 until the day of hCG administration. Daily ultrasound monitoring was performed for growing follicles and serum levels of luteinizing hormone (LH), estradiol ($E_2$) and progesterone were measured daily during cetrorelix administration. Up to 4 embryos were transferred. Results: Mean age of enrolled patients was $32.0{\pm}3.4$ years (mean $\pm$ S.D.). All of 30 patients underwent oocyte pick-up, and embryo transfer was done in 28 patients. The total and mean numbers of received oocytes were 196 and $6.5{\pm}4.7$, the number of fertilized eggs was 111, and the fertilization rate was 56.6%. Total duration of FSH administration was $9.2{\pm}2.2$ days and mean of $24.3{\pm}7.7$ ampules of HP-FSH was administered. Total duration of cetrorelix administration was $5.7{\pm}1.9$ days. Serum LH and progesterone levels were maintained in the range of $1.4{\sim}2.9\;mIU/mL$ and $0.3{\sim}0.6\;ng/mL$, which respectively reflected effective prevention of premature LH surge. Clinical pregnancies were achieved in 9 patients, and overall clinical pregnancy rate was 30.0% per oocyte retrieval, and 32.1% per embryo transfer. Conclusion: GnRH antagonist is safe and convenient for COH for IVF-ET and effective with optimal pregnancy rate.